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membraneINTRODUCTION
Mohs surgery and repair of lower eyelid surgical
defects present unique reconstruction challenges
because of risk for ectropion. There are several
options to avoid this adverse outcome, but when a
patient declines surgical repair, there are no alterna-
tives aside from second-intention healing with or
without adjunctive therapy. One promising method
is use of dehydrated human amnion/chorion mem-
brane (dHACM) allograft (EpiFix, MiMedx Group
Inc, Marietta, GA). To address the issue of a paucity
of nonsurgical repair options, the author presents 3
cases of relatively superficial lower eyelid defects
after Mohs micrographic surgery that were success-
fully repaired using dHACM.CASE REPORTS
Case 1
An 82-year-old white woman with multiple med-
ical problems (including a previous Mohs procedure
and surgical repair for a basal cell carcinoma of the
forehead) and chronic tobacco use presented to the
Mohs surgical clinic with a nodular and infiltrative
basal cell carcinoma on the right lower eyelid. After 3
stages of Mohs surgery, there was a 2.5- 3 1.5-cm
surgical defect involving almost the entire lower
eyelid, coming within 0.8 cm of the eyelid margin
and minimal extension into the underlying orbicu-
laris oculi. The patient refused surgical reconstruc-
tion because of significant pain and difficulty healing
subsequent to a previous large Mohs defect repair.
Second-intention healing was discouraged becauseBend Memorial Clinic.
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701. E-mail: Wiscooj@gmail.com.of ectropion risk; thus, the decision to use dHACM
was made, and a single dHACM allograft was
applied. The allograft was trimmed to slightly larger
than the surgical defect (2 mm larger than the defect
circumferentially), and a silicone dressing was
placed on the wound (Fig 1, A). The surgical site
was cleaned weekly with sterile saline, and another
silicone dressing was placed until the wound was
healed. The patient reported negligible pain or
bleeding compared with the previous Mohs proce-
dure. There were no complications, significant
scarring, or ectropion formation. The lesion took
45 days to heal (Fig 1, B).Case 2
A 52-year-old white woman female with medical
history significant for type II diabetes, was referred
by the ophthalmology department to the Mohs clinic
to remove a nodular basal cell carcinoma on the right
lower eyelid. After 1 stage of Mohs surgery, the
patient had a 0.6- 3 0.6-cm surgical defect directly
under the tarsal plate and hadminimal extension into
the underlying orbicularis oculi. A wedge repair or a
full-thickness skin graft was initially planned by the
ophthalmology department, but the patient declined
surgical repair. The patient agreed to try a dHACMJAAD Case Reports 2016;2:294-7.
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Fig 1. Case 1. A, Final surgical defect after Mohs surgery. B, Postoperative day 45 with the use
of a dHACM allograft.
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risk. A dHACM allograft was trimmed to slightly
larger than the surgical defect (2 mm larger than the
defect circumferentially) and was placed on the
wound (Fig 2, A). The lesion healed completely in
15 days with no complications, minimal scarring, and
no ectropion formation (Fig 2, B). The patient denied
any significant pain or bleeding. Postoperatively, a
silicone dressing was placed on the wound, but it fell
off after 2 days. Going forward, daily application of
petroleum jelly and a standard adhesive bandage
were used until the wound healed.
Case 3
An 86-year-old white man with multiple medical
problems presented to the Mohs surgical clinic with a
nodular basal cell carcinoma on the left lower eyelid.
After 3 stages of Mohs surgery, the patient had a 1.2-
3 1.1-cm surgical defect that involved the tarsal plate
but spared the eyelid margin and had minimal
extension into the underlying orbicularis oculi.
Because of the patient’s use of clopidogrel bisulfate
and aspirin, significant bleeding occurred
throughout the Mohs surgical process. Because of
this bleeding, it was decided to use a dHACM
allograft over a wedge repair or a full-thickness
skin graft. Second-intention healing was not used
because of possible ectropion formation. A dHACM
allograft was trimmed to slightly larger than the
surgical defect (2 mm larger than the defect circum-
ferentially) and was placed on the wound (Fig 3, A).
The lesion healed completely in 18 days with no
complications, minimal scarring, and no ectropion
formation (Fig 3, B). The patient denied any signif-
icant pain or bleeding. A silicone dressing was
placed on the wound and was to be replaced
5 days postoperatively. However, the dressing fell
off in 3 days. Going forward, daily application of
petroleum jelly and a standard adhesive bandage
were used until the wound healed.DISCUSSION
Mohs micrographic surgery is a precise surgical
excision technique used to remove cutaneous ma-
lignancies. The objective of the Mohs procedure is to
remove small layers of tissue until cancer-free
margins are achieved to preserve the surrounding
healthy tissue as much as possible. After Mohs
surgery, depending on the size, depth, and location
of the surgical wound, reconstruction options
include secondary intention healing, primary closure
with sutures, or local skin flaps or grafts.1,2 Surgical
defects near the eye present unique challenges for
the surgeon owing to risk for ectropion formation.
Considering this risk, repair options are limited and
secondary intention healing is discouraged.3,4 In this
case series, we describe results of 3 patients with
basal cell carcinoma and conditions associated with
poor healing who had Mohs surgery and successful
repairs with dHACM allografts.
Human amniotic membrane has been used clin-
ically in a variety of applications for more than
100 years, but there are limited data showing the
utility in the repair of cutaneous eyelid surgical
defects.5 Amniotic membrane has been identified
as a potent facilitator of wound healing in a variety of
circumstances, including lower extremity ulcers,
conjunctival reconstruction, burns, gynecologic sur-
gery, and orthopedic surgery.6-12 Key features of
amniotic membrane include an immunologically
privileged state, a reservoir of multiple growth
factors involved with tissue regeneration, and mod-
ulation of inflammatory processes. Although appli-
cation of human amniotic membrane has been used
successfully in a variety of wounds,13 difficulty in
obtaining, preparing, and storing the material and a
concern for potential for infectious disease trans-
mission, has precluded its widespread use.14 Using
dHACM minimizes the issues that arise with use of
fresh amniotic membrane. The tissue is processed
according to the American Association of Tissue
Fig 2. Case 2. A, Final surgical defect after Mohs surgery. B, Postoperative day 15 with the use
of a dHACM allograft.
Fig 3. Case 3. A, Final surgical defect after Mohs surgery. B, Postoperative day 18 with the use
of a dHACM allograft.
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the Public Health Service Act.15 Placental materials
are obtained from screened and tested donors to
ensure safety.13 The tissue is then minimally manip-
ulated using a proprietary process to create a tissue
allograft comprised of processed, dried, and steril-
ized human amnion/chorion membranes.16 Growth
factors, cytokines, and chemokines remain present
in thematerial after the proprietary processing.17 The
process also allows for storage at ambient tempera-
ture for up to 5 years and the ability to make material
available in multiple sizes and configurations for use
in a variety of wound types.
Although the exact protocol of graft application
and wound care differed in the cases above, the
recommended protocol is as follows. Standard
informed consent is obtained from the patient and
then grafts are cut to overlay the wound edge by
2 mm circumferentially. The graft is then placed in
the wound and is rehydrated by applying 1 drop of
sterile saline per 1 3 1 cm of surface area of graft or
by applying half a pea-size amount of hydrogel per
1 3 1 cm of surface area of graft. The graft is then
secured by placing a standard pressure dressing on
the wound. The graft does not need to be suturedinto place. In our cases, we used silicone dressings,
but a standard nonadherent contact layer covered by
a pressure dressing is adequate. The dressing is then
changed in the clinic every 5 to days until healed.
The 2 small cases that were approximately 1 3 1 cm
took 15 to 18 days to heal, whereas the larger 2.5- 3
1.5-cm case took 45 days to heal. It is anticipated that
for every 1.0- 3 1.0- 3 0.5-cm section (length 3
width3 depth), it should take 2 weeks to heal with 1
graft application. However, more precise data on
wound care and healing times with varying graft
application frequency need to be determined
through a larger cohort of patients.
This small sample of patients with superficial
lower eyelid defects benefited from dHACM use by
having a shorter procedure and avoiding large flap or
graft procedures, while experiencing minimal pain,
no complications, and negligible scarring. Further
evaluation of the use of dHACM after Mohs surgery
with regard to the benefits of rapid wound closure,
patient satisfaction, and pain and scar reduction
is warranted. In addition, a cost-effectiveness ana-
lysis with comparison to other allograft products
should be conducted with a larger study population.
A dHACM allograft appears to be an effective closure
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Wisco 297option for Mohs surgical defects in patients with
superficial lower eyelid defects.REFERENCES
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